A 2004 meta-analysis comprising three randomized placebo-controlled studies with a total of 173 patients suggested that<unk>  was more effective than placebo in relieving "the most bothersome gastrointestinal symptom" of functional dyspepsia as identified by each patient. Additionally, a single reference-controlled study was discussed, comparing<unk>  to the prokinetic cisapride in the treatment of "'functional dyspepsia of the dysmotility type'" and finding no significant differences in efficacy or tolerability. This paper noted that, while<unk>  seems to consistently provide symptomatic relief to patients, its efficacy is more evident "with associated symptoms of gastro-oesophageal reflux or predominance of epigastric pain." It suggests a synergy of therapeutic mechanisms provided by the complex interactions between the GI tract and each individual component of<unk> . It also supports a promising safety profile for the formulation, but notes that its results must be confirmed in larger studies in order to provide any recommendations regarding the efficacy or safety of<unk>  in the treatment of functional dyspepsia.
Iberogast
Ornge
Ipas 
Combitube
Tolibut
Archiater
Port 
Össur